Cancer

Explore the complexities of Cancer research and treatment in China’s pharmaceutical industry. At Fineline Info & Tech, we provide reliable data, news, and insights to enhance your understanding and decision-making. Stay informed and stay ahead in the fight against cancer with flcube.com.

Joincare's LZSN2501 Cleared for Phase I Clinical Trials by NMPA – Dual-Epitope Bispecific Anti-FXI Antibody Targets VTE Prevention After Total Knee Arthroplasty
CompanyDrug

Joincare’s LZSN2501 Cleared for Phase I Clinical Trials by NMPA – Dual-Epitope Bispecific Anti-FXI Antibody Targets VTE Prevention After Total Knee Arthroplasty

Joincare Pharmaceutical Group Industry Co., Ltd. (SHA: 600380) announced that its recombinant humanized anti-FXI bispecific antibody injection, LZSN2501, has been approved by China's National Medical Products Administration (NMPA) to conduct…

Hengrui's Remimazolam Tosylate Wins China Approval for ICU Sedation During Mechanical Ventilation – Ruibeining Expands Into Critical Care

Hengrui’s Remimazolam Tosylate Wins China Approval for ICU Sedation During Mechanical Ventilation – Ruibeining Expands Into Critical Care

Enhertu Wins EU Approval in Resected HER2-Positive Breast Cancer – Daiichi Sankyo's ADC Cuts Recurrence Risk by 53% Versus T-DM1

Enhertu Wins EU Approval in Resected HER2-Positive Breast Cancer – Daiichi Sankyo’s ADC Cuts Recurrence Risk by 53% Versus T-DM1

Empowering Chinese Pharma’s Global Expansion

Leverage premier media reach to connect your pipeline with global partners. Contact us to drive your international growth today.
Explore Now
Biokin Receives NMPA Approval for CD33 ADC in AML Trial
CompanyDrug

Biokin Receives NMPA Approval for CD33 ADC in AML Trial

Novocure Wins CE Mark for Optune Lua in Metastatic NSCLC Treatment
CompanyMedical Device

Novocure Wins CE Mark for Optune Lua in Metastatic NSCLC Treatment

Akeso's Ivonescimab Shows Strong Results in Phase III Trial for Sq-NSCLC
CompanyDrug

Akeso’s Ivonescimab Shows Strong Results in Phase III Trial for Sq-NSCLC

BMS Secures NMPA Approval for Opdivo in Resectable NSCLC Neoadjuvant Therapy
CompanyDrug

BMS Secures NMPA Approval for Opdivo in Resectable NSCLC Neoadjuvant Therapy

Zai Lab's Augtyro NDA Accepted by China's NMPA for NTRK Fusion Solid Tumors
CompanyDrug

Zai Lab’s Augtyro NDA Accepted by China’s NMPA for NTRK Fusion Solid Tumors

Ascentage Pharma's Oncology Drugs Lisaftoclax and Olverembatinib Gain CSCO Guidelines Inclusion
CompanyDrug

Ascentage Pharma’s Oncology Drugs Lisaftoclax and Olverembatinib Gain CSCO Guidelines Inclusion

Dizal's Golidocitinib Receives CSCO Class 1 Recommendation for PTCL Treatment
CompanyDrug

Dizal’s Golidocitinib Receives CSCO Class 1 Recommendation for PTCL Treatment

Humanwell Healthcare Gains NMPA Approval for HWS116 Clinical Trials in Advanced Solid Tumors
CompanyDrug

Humanwell Healthcare Gains NMPA Approval for HWS116 Clinical Trials in Advanced Solid Tumors

Show More